|1.||Lorenz, Todd J: 4 articles (04/2006 - 01/2005)|
|2.||Kouchoukos, Nicholas T: 3 articles (02/2008 - 10/2005)|
|3.||Mack, Michael J: 3 articles (02/2008 - 10/2005)|
|4.||PREVENT IV Investigators: 3 articles (02/2008 - 10/2005)|
|5.||Califf, Robert M: 3 articles (02/2008 - 10/2005)|
|6.||Harrington, Robert A: 3 articles (02/2008 - 10/2005)|
|7.||Ferguson, T Bruce: 3 articles (02/2008 - 10/2005)|
|8.||Peterson, Eric D: 3 articles (02/2008 - 10/2005)|
|9.||Alexander, John H: 3 articles (02/2008 - 10/2005)|
|10.||Conte, Michael S: 3 articles (01/2007 - 01/2005)|
01/01/2007 - "Edifoligide has undergone extensive clinical testing for the treatment of intimal hyperplasia following vascular bypass procedures. "
10/01/2005 - "A novel approach to preventing neointimal hyperplasia is with the double-stranded oligonucleotide edifoligide (Corgentech Inc, South San Francisco, Calif). "
01/01/2005 - "Edifoligide (E2F Decoy) is a novel therapy that inhibits E2F function, thus attenuating neointimal hyperplasia. "
02/01/2008 - "The PREVENT IV was a multicenter (107 sites) randomized trial of edifoligide to prevent vein graft failure from neointimal hyperplasia in 3,014 patients undergoing primary, isolated coronary artery bypass grafting (CABG) with at least two vein grafts. "
10/01/2005 - "Edifoligide inhibits E2F, a transcription factor that activates cell-cycle genes responsible for neointimal hyperplasia. "
11/01/2009 - "PREVENT III was a randomized controlled trial, designed to test the efficacy of edifoligide versus placebo in patients undergoing vein bypass for critical limb ischemia (CLI). "
04/01/2006 - "The PREVENT III study was a prospective, randomized, double-blinded, multicenter phase III trial of a novel molecular therapy (edifoligide; E2F decoy) for the prevention of vein graft failure in patients undergoing infrainguinal revascularization for critical limb ischemia (CLI). "
07/01/2006 - "Recently, PRoject of Ex vivo vein GRaft Engineering via Transfection (PREVENT) III and IV demonstrated that edifoligide failed to benefit human vein grafts employed to treat lower-extremity ischemia and coronary heart disease, respectively. "
|3.||Peripheral Arterial Disease
|4.||Vascular Diseases (Vascular Disease)
|5.||Wounds and Injuries (Trauma)
|1.||Transcription Factors (Transcription Factor)
|2.||E2F Transcription Factors
|2.||Coronary Artery Bypass (Coronary Artery Bypass Surgery)